Very proud of Darrin Miles for sharing our incredible progress at #AACR24! This is all possible thanks to our exceptionally dedicated team!
𝐀𝐀𝐂𝐑𝟐𝟒: Having entered the clinic last night, Nested Therapeutics' CEO Darrin Miles discusses the preclinical profile of a brain-penetrant, pan-RAF/MEK molecular glue. #AACR24 Full video: https://lnkd.in/gsBc2yEu BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
Our CEO, Dr. J. Jean Cui, connected with BiotechTV’s Brad Loncar following our completion of a $100 million financing to gain insight into Dr. Cui’s perspective on #precisionmedicines and how we are working to solve unmet medical needs by re-envisioning #cancer drug development. Watch the full video here: https://bit.ly/3Isffxy
𝐅𝐮𝐧𝐝𝐫𝐚𝐢𝐬𝐢𝐧𝐠 𝐍𝐞𝐰𝐬: BlossomHill Therapeutics, Inc. raises a $100M series B to work on precision medicine small molecules. Scientific founder, president & CEO J. Jean Cui describes the company's approach. Full video: https://lnkd.in/gfYWVuUT BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
Listen to one of the presenting companies at today's #AlignSummit24 speak with Brad Loncar.
𝐀𝐥𝐢𝐠𝐧 𝐒𝐮𝐦𝐦𝐢𝐭: Myrobalan Therapeutics' CEO Jing Wang describes the challenge of aiming to develop restorative therapies in CNS through remyelination and anti-neuroinflammation. "Someone has to work on that even though it's hard." #AlignSummit24 Full Video: https://lnkd.in/gdn7RV9U BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
A great insight into why treating complex CNS diseases is such a recalcitrant challenge! I hope Myrobalan Therapeutics can utilise these mechanisms to create a successful FIC molecule! #biotech #CNS #neurogeneration #neurology #microglia #demyelination
𝐀𝐥𝐢𝐠𝐧 𝐒𝐮𝐦𝐦𝐢𝐭: Myrobalan Therapeutics' CEO Jing Wang describes the challenge of aiming to develop restorative therapies in CNS through remyelination and anti-neuroinflammation. "Someone has to work on that even though it's hard." #AlignSummit24 Full Video: https://lnkd.in/gdn7RV9U BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
Capitalizing on ADC frenzy, ProfoundBio attracts $112M series B https://lnkd.in/gapyis_t With Big Pharmas heading into 2024 with a renewed interest in antibody-drug conjugates (ADCs), it’s no surprise that ProfoundBio managed to assemble a who’s who of biotech investors for an oversubscribed series B round. Source: Capitalizing on ADC frenzy, ProfoundBio attracts $112M series B
Today's the day. Check out my presentation at Fierce Biotech JPM week on success factors for the biotech company journey from discovery to commercialization. You can register here. https://lnkd.in/eQTYR4nE
Head of Marketing & Communications (ASX: OPL) Clinical Trial Design SaaS + Biotech Investment Tool - Ex Koala & Silverbean
Exciting Partnership Announcement! I am thrilled to share that Opyl has partnered with L39 Capital to launch an AI Biotech Fund. This groundbreaking initiative will leverage our proprietary TrialKey technology to revolutionise biotech investments. This AI Biotech Fund has an aim for $100M in AUM within 36 months. Using TrialKey’s predictive power, we’re identifying high-return biotech stocks initially in the US and Australia. TrialKey’s model identified over 200 annual inflection points, providing investors with precise entry and exit opportunities for maximum returns. Book a demo:https://lnkd.in/gtb--GRr Marketing and investor enquiries: bernice.averion@opyl.ai #ai #biotech #biofund #opyl #investment #clinicaltrials #pharma #biopharma #bioinvestments #investments #medtech #asx #nasdaq #medicalresearch #medicalinnovation
Europe often looks at the USA when it comes to digital innovation. Is that the same when it comes to digital therapeutics and market access? - With Jonas Albert Listen to the full episode here: https://lnkd.in/gEd3ndpH #DTx #DiGA #DiPA #digitalhealth #lifesciences
Do you want to improve your method development, transfer, and scaling? Join us in this FREE two-part #webinar series! Is your agenda already full? Register anyway and we'll send you an on-demand recording a few days after the event: https://bit.ly/3XC93K0 Part 1: Robust Method Development and Optimization for Characterizing #Biotherapeutics (18. July) Part 2: Successful Scaling and Transfer of Biotherapeutic Characterization Methods (24. August)
Its a key question - What Does 2024 Hold For Biopharma? Part 2 of its new year Citeline #ScripAsks article series what leaders across the industry predict. Our CEO Eliot Forster predicts that M&A will be driven by the ongoing fundamental demand for late-stage development and commercial assets as big pharma and big biotech look to bolster portfolios in the face of looming patent expiries. Levicept looks forward to data this year from our phase II study of LEVI-04 in patients with osteoarthritis of the knee. LEVI-04 is a biological therapy (LEVI-04 [p75NTR-Fc]) being developed for the treatment of chronic pain. Watch this space! Read the ScripAsks article here - https://lnkd.in/eCKp9ZMA #biotech #drugdevelopment #chronicpain #osteoarthritis
Dystrophic Epidermolysis Bullosa Market to Expand at a Significant Growth Rate During the Forecast Period (2023-32) – Estimates DelveInsight | Eloxx, Krystal Biotech, Phoenicis, Quoin, RegeneRx: Delveinsight Business Research LLP As per DelveInsight, in the seven major markets, the Dystrophic Epidermolysis Bullosa market size was found to be USD 500 Million in 2021. The Dystrophic Epidermolysis Bullosa Market is set to register immense growth in the … Continue reading → #Finance #FinancialMarket #MarketingSales #PharmaceuticalsBiotech
Medical and Scientific Affairs Leader
3moCongratulations Darrin and Nested team!